Dutasteride: A Guide to Its Use as Monotherapy in Benign Prostatic Hyperplasia

The document reviewed the use of dutasteride as monotherapy for managing benign prostatic hyperplasia (BPH). Dutasteride, a dual 5α-reductase inhibitor, was shown to significantly reduce dihydrotestosterone levels, leading to improvements in both objective and subjective measures of BPH. Long-term studies demonstrated sustained symptom relief and enhanced quality of life for patients. The drug was also found to be safe and well-tolerated, with a favorable risk-benefit profile. Additionally, combination therapy with dutasteride and other medications like tamsulosin provided further symptom improvement in men with larger prostates.